2666 related articles for article (PubMed ID: 19002123)
1. The role of combination medical therapy in benign prostatic hyperplasia.
Greco KA; McVary KT
Int J Impot Res; 2008 Dec; 20 Suppl 3():S33-43. PubMed ID: 19002123
[TBL] [Abstract][Full Text] [Related]
2. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate.
Naslund MJ; Miner M
Clin Ther; 2007 Jan; 29(1):17-25. PubMed ID: 17379044
[TBL] [Abstract][Full Text] [Related]
3. Treatment of lower urinary tract symptoms in benign prostatic hyperplasia and its impact on sexual function.
Miner M; Rosenberg MT; Perelman MA
Clin Ther; 2006 Jan; 28(1):13-25. PubMed ID: 16490576
[TBL] [Abstract][Full Text] [Related]
4. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
[TBL] [Abstract][Full Text] [Related]
5. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Becher E; Miñana B; Mirone V; Castro R; Wilson T; Montorsi F;
Eur Urol; 2009 Feb; 55(2):461-71. PubMed ID: 19013011
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study.
Yang Y; Zhao XF; Li HZ; Wang W; Zhang Y; Xiao H; Zhang X
Chin Med J (Engl); 2007 Mar; 120(5):370-4. PubMed ID: 17376305
[TBL] [Abstract][Full Text] [Related]
7. A review of combination therapy in patients with benign prostatic hyperplasia.
McVary KT
Clin Ther; 2007 Mar; 29(3):387-98. PubMed ID: 17577460
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design.
Siami P; Roehrborn CG; Barkin J; Damiao R; Wyczolkowski M; Duggan A; Major-Walker K; Morrill BB;
Contemp Clin Trials; 2007 Nov; 28(6):770-9. PubMed ID: 17761460
[TBL] [Abstract][Full Text] [Related]
9. The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia.
Fitzpatrick JM; Desgrandchamps F
BJU Int; 2005 Mar; 95(4):575-9. PubMed ID: 15705083
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
[TBL] [Abstract][Full Text] [Related]
11. Current role for combination therapy in male LUTS.
Chung DE; Kaplan SA
Arch Esp Urol; 2010 Jun; 63(5):323-32. PubMed ID: 20587837
[TBL] [Abstract][Full Text] [Related]
12. Effects of serum PSA on efficacy of tolterodine extended release with or without tamsulosin in men with LUTS, including OAB.
Roehrborn CG; Kaplan SA; Kraus SR; Wang JT; Bavendam T; Guan Z
Urology; 2008 Nov; 72(5):1061-7; discussion 1067. PubMed ID: 18817961
[TBL] [Abstract][Full Text] [Related]
13. Anticholinergic therapy for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Gallegos PJ; Frazee LA
Pharmacotherapy; 2008 Mar; 28(3):356-65. PubMed ID: 18294115
[TBL] [Abstract][Full Text] [Related]
14. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
[TBL] [Abstract][Full Text] [Related]
15. Treatment of lower urinary tract symptoms suggestive of benign prostatic hyperplasia: sexual function.
Lowe FC
BJU Int; 2005 Jun; 95 Suppl 4():12-8. PubMed ID: 15871731
[TBL] [Abstract][Full Text] [Related]
16. Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.
Gacci M; Eardley I; Giuliano F; Hatzichristou D; Kaplan SA; Maggi M; McVary KT; Mirone V; Porst H; Roehrborn CG
Eur Urol; 2011 Oct; 60(4):809-25. PubMed ID: 21726934
[TBL] [Abstract][Full Text] [Related]
17. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
[TBL] [Abstract][Full Text] [Related]
18. Effect of dutasteride, tamsulosin and the combination on patient-reported quality of life and treatment satisfaction in men with moderate-to-severe benign prostatic hyperplasia: 4-year data from the CombAT study.
Montorsi F; Henkel T; Geboers A; Mirone V; Arrosagaray P; Morrill B; Black L
Int J Clin Pract; 2010 Jul; 64(8):1042-51. PubMed ID: 20487046
[TBL] [Abstract][Full Text] [Related]
19. The effects of dutasteride, tamsulosin and combination therapy on lower urinary tract symptoms in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the CombAT study.
Roehrborn CG; Siami P; Barkin J; Damião R; Major-Walker K; Morrill B; Montorsi F;
J Urol; 2008 Feb; 179(2):616-21; discussion 621. PubMed ID: 18082216
[TBL] [Abstract][Full Text] [Related]
20. Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice.
Vallancien G; Emberton M; Alcaraz A; Matzkin H; van Moorselaar RJ; Hartung R; Harving N; Elhilali M;
BJU Int; 2008 Apr; 101(7):847-52. PubMed ID: 18321317
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
